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Staphylococcus aureus is a Gram- positive bacterium that can cause serious infections, 
often leading to sepsis, which can be fatal.  By focusing on the infection process ofS. 
aureus, we hope to characterize the mechanism by which the bacterium is entering the 
cell. Our hypothesis is that the protein, p85, is integral in the infection process.  To 
investigate the role of  a domain of  p85, known as the Rho  GAP domain, we will over­
express this domain in the host cell and assess its effect on S. aureus infection. 2 
INTRODUCTION 
Severe sepsis is a common, expensive, and frequently fatal condition, with as 
many deaths annually as those from acute myocardial infarction (Angus, 2001). The 
pathophysiological process ofsepsis is a disease continuum from infection, signs and 
symptoms of  infection, sepsis, severe sepsis, and multi-organ dysfunction (Gao, 2008). 
Staphylococcus aureus  has long been recognized as a major human pathogen responsible 
for a wide range of  infections, from mild skin infections to wound infections and 
bacteraemia (Hardy, 2004). Staphylococcus aureus is characterized as a Gram-positive 
bacterium. Signs and symptoms of  infection that may result in sepsis include temperature 
> 38.3°C or < 36.0°C, heart rate below 90 beats per minute, and hyperglycemia in the 
absence ofdiabetes (Gao, 2008).  Sepsis is most often treated with various antibiotics, but 
depending on the severity ofthe case, even antibiotics may not counteract the infection 
caused by the bacterial invasion. Numerous trials have been conducted of  agents that 
block the inflammatory cascade that causes sepsis, including corticosteroids, anti­
endotoxin antibodies, tumor necrosis factor (TNF) antagonists, interleukin-1-receptor 
antagonists, as well as several other agents (Hotchkiss 2003).  However, over time S. 
aureus has developed drug-resistance, especially to certain antibiotics.  One ofthe most 
common strains of  the bacteria is known as MRSA, or Methicillin Resistant 
Staphylococcus aureus.  As of2001, MRSA accounted for greater than 40% oftotal S. 
aureus cases, which is an increase from -2% in the early 90's (Hardy, 2004). Intensive 
care patients are at great risk of  infection from MRSA. They have increased risk factors, 3 
including extended stays in hospitals, high antibiotic consumption and numerous i.v. 
devices inserted. The severity oftheir underlying disease also means that the 
consequences ofinfection with MRSA cause significant morbidity or mortality. One 
reason for the failure ofanti-inflammatory strategies in patients with sepsis may be a 
change in the syndrome over time. Initially, sepsis may be characterized by increases in 
inflammatory mediators; but as sepsis persists, there is a shift toward an anti­
inflammatory immunosuppressive state (Hotchkiss 2003). An immunosuppressive state is 
a state in which the immune response by the body is lowered.  Due to the lowered 
immune response, it is much harder to treat sepsis, especially with antibiotics or other 
drugs.  A class ofdrugs that has been shown to have a positive effect on the outcome of 
patients with sepsis is statins. The statins are a class of  lipid-lowering drugs which inhibit 
the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (Gao, 
2008). HMG-CoA reductase catalyses the conversion ofhydroxy  methyl glut  aryl-Co  A to 
mevalonate, an early rate-limiting step in cholesterol biosynthesis, leading to cholesterol­
lowering effects. HMG-CoA reductase inhibitors (statins) have been shown to exhibit 
important biological effects independent of  lipid lowering (Merx, et aL 2005).The clinical 
studies that have described effects ofstatins in sepsis have either addressed the effects of 
statins in reducing sepsis incidence/severity or retrospectively looked at mortality in 
those taking statins who developed sepsis (Gao, 2008). Since those studies, there has 
been a big emphasis studying statins, especially simvastatin.  Basic research with statins 
has focused on blocking steps within the inflammatory cascade associated with sepsis. In 
the lab, we have focused on the cholesterol biosynthesis pathway and the way in which 
simvastatin is involved.  We hope to imitate the effects ofthe drug in vitro and better 4 
understand the mechanism by which the bacteria seem to exploit the host cell for 
invasion. By altering different aspects ofthe endocytic pathway, we hope to uncover a 
mechanism for preventing S.  aureus from entering the cell. 
The mechanism by which statins modulate the immune response is complex, but 
is often regarded as lipid independent as they are not related to lowering LDL cholesterol 
(Gao, 2008). These effects primarily involve the inhibition of  isoprenoid lipid production 
and subsequent protein prenylation (Greenwood, 2006). Examples ofthe isoprenoid 
intermediates include geranylgeranyl pyrophosphate (GGpp) and famysylpyrophosphate 
(Fpp).  Once this was established, each component ofthe pathway was studied 
individually to determine which component ofthe pathway was indeed affecting the 
ability ofS.  aureus to invade the cells. 
The first step in narrowing it down to the specific component that was affecting 
bacterial invasion was to start by adding certain intermediaries ofthe pathway back to 
cells that had been pre-treated with simvastatin to determine where bacterial invasion was 
being blocked by simvastatin. By introducing cholesterol, an end product ofthe pathway, 
back into the cells, invasion was not restored (Hom, 2008).  Therefore, it was determined 
that cholesterol is not necessary for bacterial invasion.  Other intermediaries such as 
GGpp and Fpp were also added back into the cells, and it was observed that they were 
able to completely or partially restore invasion into the cells. Therefore, we were able to 
conclude that intermediaries within the cholesterol biosynthesis pathway, such as GGpp 
and Fpp are necessary for bacterial invasion, but the end product, cholesterol is not. 
Through understanding of  cellular invasion by other types ofbacteria, it is 
believed that molecular cell signaling pathways and cytoskeletal rearrangements are very 5 
important in invasion. S.  aureus is able to invade eukaryotic cells by indirectly engaging 
PI  integrin-containing host receptors (Agerer, 2003). We began to study the molecular 
signaling that enables the components of  the cytoskeleton to rearrange to allow for 
bacteria to invade the cell.  There are several parts of  the signaling process that we 
believe to be necessary for bacteria, specifically S.  aureus, to enter the cell.  At the cell 
surface, there are several receptors and binding proteins that enable certain substances to 
cross the cell membrane.  The first is fibronectin, which is an extracellular matrix protein 
that is often found on the cell surface. Internalization ofS.  aureus involves an interaction 
between fibronection binding protein (FnBp) and the host cell, resulting in signal 
transduction, tyrosine kinase activity, and cytoskeletal rearrangement ( Dziewanowska, 
1999). In order to gain entry to the cell, S. aureus has proteins on its surface, collectively 
named, MSCRAMMS (microbial surface components recognizing adhesive matrix 
molecules) (Alexander, 2001). Host cells also contain surface receptors that recognize 
and bind to fibronectin, most notably, the integrin asPI.  Due to this receptor, S.  aureus is 
often able to bind to the cell surface and almost directly come into contact with the a5Pl 
integrin (Sinha, 1999).  This interaction initiates the process by which S.  aureus is able to 
be internalized by the cells through cytoskeletal rearrangements.  Integrins transmit 
important extracellular information such as cell attachment, matrix composition, and 
rigidity, into the cell. Once these integrin-protein complexes have been made, several 
other types of  protein and protein complexes start to form on the inner side of  the cellular 
membrane. 
In our lab, we believe that phosphoinositide 3-kinase is necessary for host cell 
invasion by S.  aureus. Previous studies in the lab have shown that inhibition ofPI3K 6 
decreases actin stress fiber disassembly and S.  aureus invasiveness (Hom, 2008). This 
was determined by using the PI3K inhibitor, L  Y294002. In a dose-dependent manner, the 
inhibitor, L  Y294002, inhibited S.  aureus host cell invasion. 
PI3K is a heterodimer commonly composed of  one ofthree catalytic subunits 
(pllOo., pIIO~, pllOo) and one of  five regulatory subunits (P85o.,  p85~, p85y, p55o., 
p50o.) (Geering, 2007). In order to broaden our understanding ofPI3K, we have done 
several projects aimed at understanding the role of PI3K in endocytosis. Mammalian cells 
take up extracellular material by a variety ofdifferent mechanisms that are collectively 
termed endocytosis (Mukherjee, 1997). 
The endocytosis process is ofcritical importance for a variety ofcellular life 
functions (Qualmann, 2000). Endocytic mechanisms serve many important cellular 
functions including the uptake ofextracellular nutrients, regulation of  cell-surface 
receptor expression, maintenance ofcell polarity, and antigen presentation. Endocytic 
pathways are also utilized by viruses, toxins, and symbiotic microorganisms to gain entry 
into cells. 
The extracellular matrix controls cytoskeletal organization through several 
distinct signal transduction pathways regulated by different members of  the Rho family 
of GTPases (Clark, 1998). More specifically, actin reorganization is dependent on both 
Cdc42 and Rae.  It has been suggested that Rho GTPases are involved in endocytosis, 
however the connection between the two activities is not completely understood 
(Fernandez-Borja, 2005).  Therefore, our lab is interested in the role that these small 
GTPases play in the endocytosis ofS.  aureus. The small GTPases are known to interact 
with PI3K via a binding domain ofthe p85a. isoform (Zheng, 1994).  The RhoGAP 7 
domain is a 200-residue conserved segment, which has been found in a large group of 
proteins, including p85 (Musacchio, 1996).  The ability ofthe PI3K RhoGAP domain to 
interact with small GTPases, Rac1  and Cdc42 may be important for translocating PI3K to 
membranes and for stimulating its catalytic activity. For the next step of  the endocytic 
pathway to occur, the prenylated small GTPase bound to PI3K must be anchored near the 
cell membrane. By doing so, this brings the catalytic domain ofPI3K, plIO, close to 
phosphoinositide. 
Phosphoinositide (PI), normally found to be dually phosphorylated, (PI 4,5), 
becomes phosphorylated by an interaction with PI3K (Vanhaesebroeck, 2001). 
Phosphoinositide is normally found in the cytosol.  When the catalytic domain ofPI3K, 
p 110, is brought into the proximity of  PI, it can then phosphorylate the substrates 
phosphoinositide (PI), PI -4-phosphate (PIP), and PI-4,5-phosphate (PIP2)'  PIP2 appears 
to be most readily used by the Class IA PI3Ks.  Therefore, when PIP2 becomes 
phosphorylated by PI3K, it becomes PI-3,4,5-phosphate (PIP3). 
oc-Actinin is a 100 kDa actin binding protein (Lee, 2004). We believe that oc­
actinin may playa role in integrin-mediated internalization of  bacterial pathogens 
Localization of  this protein is key in determining its function.  Studies suggest that a­
actinin interacts with phosphoinositides, which regulate its activity within the cell 
(Fraley, 2005). More specifically, it interacts with the phosphates at the 4th and 5
th 
position ofthe inositol head group.  Phosphoinositide binding of  a-actinin inhibits it from 
interacting with actin filaments, by blocking its actin-binding domain (Fraley, 2003). 
Since a-actinin becomes bound to PIP3, and its actin-binding domain is blocked, actin 
stress fibers are believed to disassemble due to the loss of  contact with a-actinin. Actin 8 
stress fibers enable the cell membrane to maintain its shape and motility (Chant, 1995). 
However, since the actin stress fibers are removed, the cell membrane loses its rigidity 
thus allowing the bacteria to enter the cell. 
We believe that simvastatin plays an important role in the endocytic mechanism 
that S.  aureus uses to gain entry into the cell. Given that we do not know the exact 
function that simvastatin plays in this process, several members in the lab have worked 
on different projects aimed at determining its precise role.  We believe that simvastatin 
reduces bacterial invasion by forcing Cdc42 coupled to PI3K to accumulate in the 
cytosol. By sequestering PI3K in the cytosol, Cdc42 is restricted from interacting with PI 
at the membrane. Therefore, since PIP2 is not phosphorylated, a-actinin is allowed to 
remain intact with the actin stress fibers. Because the stress fibers are allowed to remain 
intact, the forces necessary for endocytosis to occur are removed, thus keeping S.  aureus 
on the outside of  the cell. 
The specific project that I worked on focused mainly on the role ofthe RhoGAP 
domain in the endocytic process of  S.  aureus.  The hypothesis is that the over expression 
of  the RhoGAP domain ofp85 will compete with endogenous p85 for binding to small 
GTPases, limiting the recruitment ofendogenous p85 to the cell membrane.  Therefore, 
the endogenous p85 cannot interact with the small GTPase Cdc42 and therefore cannot 
translocate to the cell membrane.  IfPI3K and the small GTPase cannot localize to the 
cell membrane, the endocytic pathway that the bacteria uses will be broken.  If  our 
hypothesis is correct, S.  aureus will not be able to enter the cell and infection will not 
occur. 9 
MATERIALS AND METHODS 
Amplification of RhoGAP Domain from p85 WT DNA 
By amplifying the RhoGAP domain from p85 WT DNA, we will be able to over express 
this domain in host cells, in order to assess the inhibition ofS.aureus.  p85 WT DNA was 
obtained from Origene (#SC115320; Rockville, MD).  Primers were designed in order to 
amplify the specific DNA region of  interest, the Rho  GAP domain.  A forward primer was 
designed to be 27 base pairs long, and the reverse primer was designed to be a 28 base 
pair reverse complement to the forward primer.  The base pair sequences were as follows: 
RhoGAP  Forward Primer:  CAC CGC AGA TGT  TGA ACA ACA AGC TTG 
RhoGAP Reverse Primer:  CTA CTG TCG  TTC  ATT  CCA TTC  AGT  TGA G 
An Accuprime Pfx SuperMix (Invitrogen #12344-040) was used. This mix includes the 
polymerase, which is important in the polymerase chain reaction or PCR reaction. The 
primers, along with this polymerase were combined with p85 WT DNA and were run on 
the following cycle: 
1 cycle:  95° C for 2.5 min. 
35 cycles:  95° C for 15 sec 
60° C for 1 min 
72° C for 1 min 
Remains at 4° C after above cycles are complete. 10 
The polymerase along with the primers will amplify the DNA going forward and 
backward, so that only the fragment of  interest remains, the Rho  GAP domain of  p85.  In 
order to determine ifthe correct fragment was obtained, the PCR sample was run on a 1% 
agarose gel at 80 V for I hour. The expected size of  the RhoGAP domain fragment is 550 
b.p. 
Cloning into pENTRID-TOPO Vector 
The amplified fragment, RhoGAP domain of  p85, was cloned into the pENTRlD-TOPO 
vector using a TOPO Cloning Kit (Invitrogen #45-0218) according to manufacturer's 
instructions.  The reaction was then transformed into OneShot Top  1  0 Competent cells 
(Invitrogen #44-0301).  A control sample of  pENTR DNA was also transformed into the 
OneShot cells.  A 1 I-lL PCR sample was added to components ofthe kit, including 1 I-lL 
ofthe pENTRlD-TOPO vector to reach a final volume of6 1-lL.  2 I-lL of  the TOPO 
Cloning reaction was introduced into the OneS  hot Top 10 cells; 1 I-lL ofthe pENTR 
control DNA was introduced into a separate tube of  OneShot Top 10 cells.  The cells 
were incubated on ice for 15 minutes, and then heat shocked in a 42° C water bath for 30 
sec.  RT SOC medium was then added at a volume of250 I-lL to the tubes and were then 
placed in shaking incubator at 37° C for 1 hour.  Cells from each tube were then spread 
on kanamyacin plates in three separate volumes (50, 100,200 I-lL), in order to vary the 
amount of  cells on each plate.  Plates were then inverted in bacterial incubator ON. Five 
colonies were chosen from the experimental plates and grown at 37° C overnight in L­
broth (Q Biogene #3001-221) containing 50 mglmL kanamycin. 11 
Extraction of  DNA from Bacterial Cells 
A QIAPrep Spin Mini Kit (Qiagen #27104) was used to extract the DNA from the 
bacterial overnight cultures of  RhoGAP/pENTRID-TOPO #1-5.  The samples were first 
centrifuged for 1 min at 14,000 rpm in order to pellet the bacterial cells.  This step was 
repeated in order to obtain a larger amount of  cells.  The cells were  resuspended in a 
combination of  buffers in order to lyse open the cells.  The plasm  ids were  isolated by 
centrifugation and the supernatant was transferred to the QIAPrep column.  The samples 
were subjected to a series of  washes followed by centrifugation in order to isolate the 
plasmid.  The column is designed to bind the plasmid, so the plasmid can be eluted by 
water after purification.  A portion ofthe sample was separated to be used for restriction 
digest analysis and the remainder was saved in the case ofthe correct clone being 
obtained. 
Restriction Digest to Assess Clones 
Restriction enzymes were identified that could be used to confirm ifcloning was 
successful. For each sample, 8 ilL of  DNA was combined with 2 ilL React 2 buffer and 
1 ilL Hind III enzyme for a final volume of 10 ilL.  An undigested sample was also run 
using one ofthe samples, which consisted of  8 ilL of DNA and 2 J.1L of  water.  The 
samples were digested at 37° C for 1 hour.  After digestion, 2 J.1L  lOX Blue Juice 
(Invitrogen # 10816-015) was added to each ofthe samples.  The samples were run on a 
1% agarose gel at 80V for 1 hour. The gel was imaged to determine ifthe correct 
construct was obtained.  If  cloning was successful, the expected band sizes were -2900 12 
and 341  b.p.  In order to further isolate the correct mutant, a separate restriction digest 
was performed on four ofthe six samples. For this digest, 17 ilL ofthe samples 
RhoGAP/pENTRID-TOPO #'s 1,3,5,6 were digested with 2 ilL NEB Buffer #2 and 1 ilL 
ofNhe I.  An undigested sample was also run using 17 ilL of  sample #1  and 3 ilL of 
water.  Samples were digested at 37° C for 1 hour.  After digestion, 2 JlL of lOX Blue 
Juice was added to each ofthe samples.  The samples were then run on a 1  % agarose gel 
at 80V for 1 hour. The gel was then imaged in order to determine ifthe correct construct 
was obtained.  For this digest, expected band sizes were again -2900 and 341  b.p. ifthe 
cloning was successfuL 
Large Scale Plasmid Prep of RhoGAP Construct 
Bacteria from each of  the overnight cultures used in the mini preps were used to start an 
8-hour sample.  The bacteria were grown in 5 mL of L-broth containing 50 mg/mL 
kanamycin. From these 8-hour samples, overnight cultures were  grown in 100 mL of L­
broth containing 50 mg/mL kanamycin in 37° C shaking incubator.  DNA was then 
extracted from each ofthe two samples using an Endofree Plasmid Maxi Kit (Qiagen 
#12362) according to manufacturer's instructions. Overnight culture samples were 
centrifuged in order to pellet the cells.  Cells were then lysed open to release the DNA 
using a combination ofbuffers. The cellular components were then separated from the 
plasmid DNA during centrifugation.  This supernatant was added to the QIAPrep column, 
which binds the plasmid DNA, which can then be eluted using water.  The absorbance of 
the constructs was measured at 260 nm using a spectrophotometer.  From this reading, 
the concentration ofthe two samples was calculated.  A restriction digest of  these 
samples was run in order to verify that the correct clone was obtained.  Both samples 13 
were digested with Nhe I and Hind III restriction enzymes separately at 37°C for one 
hour.  Digests were prepared with Blue Juice loading buffer and run on a 1  % agarose gel 
at 80 V for one hour.  Expected band sizes were 2900 and 341 b.p. if  the correct clone 
was obtained. 
Recombining into pcDNA3.1nV5IDEST Vector 
Once large scale preps were performed on the two RhoGAP/pENTRID-TOPO samples 
#3 and #5, transformation into a new vector began.  An LR recombination reaction was 
performed for each of  these samples.  3 ilL of  each RhoGAP/pENTRlD-TOPO sample 
was added to 2 ilL ofthe destination vector, pcDNA3.1nV5/DEST (Invitrogen #12290­
010),4 ilL of 5X LR Clonase Reaction Buffer, and TE Buffer: pH 8.0 to a final volume 
of 16 ilL.  The LR Clonase enzyme was then added to the reaction at a volume of  4 ilL, 
and mixed well by vortexing briefly.  Reactions were incubated at 25° C overnight. 
Proteinase K was then added at a volume of2 ilL the next day to terminate the reaction. 
The samples were vortexed briefly and then incubated at 37°C for 10 minutes. The 
resulting sample, RhoGAP/pcDNA3.1nV5/DEST was transformed into One Shot Top 10 
competent cells as described previously.  The DNA was isolated using a QIAPrep Spin 
Mini Kit and the isolated DNA samples were analyzed by a restriction digest, using the 
enzymes Pst I and Bam HI separately.  The plasmid was digested at 37°C for 1 hour and 
then run on a 1% agarose gel at 80V for 1 hour.  For the digest with Pst I, if  the plasmid 
construct was in the correct orientation in the destination vector, expected band sizes 
would be -4111 and ~2000  b.p. For the digest with Bam HI, if  the construct was in the 
correct orientation in the vector, expected band size would be ~6200  b.p. 14 
Large Scale Plasmid Prep of RhoGAP/pcDNA3.1n  V5IDEST #5D 
Bacteria from an overnight sample ofmini-prep #5D was used to start an 8-hour sample. 
The bacteria were grown in 5 mL ofL-broth containing ampicillin.  From these 8-hour 
samples, overnight cultures were then grown in 100 mL of  L-broth containing ampicillin 
at 37° C shaking incubator.  DNA was then extracted from the sample using an Endofree 
Plasmid Maxi Kit according to manufacturer's instructions as described previously. The 
absorbance of  the constructs was measured at 260 nm using a spectrophotometer.  From 
this reading, the concentration ofthe sample was calculated.  A restriction digest ofthe 
sample was run in order to verify that the correct clone was obtained.  A restriction digest 
was run on #5D using the restriction enzymes Pst I and Bam HI at 37°C for one hour. 
Digests were then run on a 1  % agarose gel at 80 V for one hour.  Expected band sizes for 
digest with Pst I were 4111  and 2000 b.p. if  correct.  Expected band size for digest with 
Bam HI was 6200 b.p. if  correct. 
Analysis of Mutant by DNA Sequencing 
Once it appeared that the correct mutant had been obtained, the DNA was sent away for 
sequence confirmation.  One sample ofthe DNA was sent to a sequencing facility at the 
University of  California, Davis.  Primers were designed according the predicted fragment 
size and sequence.  The primers were designed in VectorNTI and sent along with the 
mutant DNA to the sequencing facility.  Primers were designed to be at least 18 b.p. in 
length, with a O/C content between 50-55%, and a melting temperature between 50­
70°C.  Sequences obtained from UC Davis were then analyzed using the program 15 
"Chromas."  The sequence will be sent in different lengths depending on the number of 
primers used.  A contig was then created from these sequences.  This contig was aligned 
with the DNA sequence originally designed for the mutant in order to determine ifthe 
correct clone was obtained. 
Cloning into pENTRID-TOPO Vector 
A new cloning reaction was performed using the RhoGAP PCR product.  The TOPO 
cloning reaction was performed using a TOPO Cloning Kit and was done according to 
manufacturer's instructions.  The new RhoGAP/pENTRID-TOPO bacterial cultures, as 
well as original RhoGAP/pENTRID-TOPO Mini Prep #6 bacterial cultures, were 
transformed using OneShot Top 10 competent cells as described previously.  The plasmid 
DNA was isolated from the cells using a Qiaprep Spin Mini Kit according to 
manufacturer's instructions.  A restriction digest was performed on the plasmid DNA 
samples.  The samples were digested using both Hind III and Eco RVat 3r  C for 1 hour. 
Digests were run on a 1  % agarose gel at 80V for 1 hour.  If  the correct construct 
orientation is achieved, expected band sizes would be big, 374 and 341 b.p. 
Large Scale Plasmid Prep of RhoGAP/pENTRID-TOPO #14 
Bacteria from an overnight culture was used to start an 8-hour culture, which was then 
used to start an overnight culture.  DNA was extracted using an EndoFree Plasmid Maxi 
Kit according to manufacturer's instructions. The absorbance was read using a 
spectrophotometer, and the concentration was then calculated.  A restriction digest was 
performed on the sample using EcoRV and Hind III at 37°C for 1 hour.  The digests 
were run on a 1  % agarose gel at 80V for 1 hour.  Expected band sizes if  the correct 
construct was obtained are big, 374 and 341  b.p. 16 
Analysis of Mutant by DNA Sequencing 
Once it appeared that the correct mutant had been obtained, the DNA was sent away for 
sequence confirmation.  One sample ofthe DNA was sent to a sequencing facility at the 
University of  California, Davis.  Primers were designed according the predicted fragment 
size and sequence.  The primers were designed in VectorNTI and sent along with the 
mutant DNA to the sequencing facility.  Primers were designed to be at least 18 b.p. in 
length, with a G/C content between 50-55%, and a melting temperature between 50-70° 
C.  Sequences obtained from UC Davis were then analyzed using the program 
"Chromas."  The sequence will be sent in different lengths depending on the number of 
primers used.  A contig was then created from these sequences.  This contig was then 
aligned with the DNA sequence originally designed for the mutant in order to determine 
if  the correct clone was obtained. 
Recombining into pcDNA3.1nV5IDEST Vector 
An LR recombination reaction was performed using the RhoGAP/pENTRlD-TOPO #14 
sample. 3 JlL ofthe RhoGAP/pENTRID-TOPO sample was added to 2 ilL of  the 
destination vector, pcDNA3.1nV5/DEST, 4 JlL of5X LR Clonase Reaction Buffer, and 
TE Buffer: pH 8.0 to a final volume of 16 JlL.  The LR Clonase enzyme was then added 
to the reaction at a volume of  4 ilL and mixed well by vortexing briefly.  Reactions were 
incubated at 25° C overnight.  Proteinase K was then added at a volume of  2 JlL the next 
day to terminate the reaction. The samples were vortexed briefly and then incubated at 
37°C for 10 minutes. The resulting sample, RhoGAP/pcDNA3.1nV5/DEST #14 was 
transformed into One Shot Top 10 competent cells as described previously.  The DNA 
was then isolated using a QIAPrep Spin Mini Kit and the isolated DNA samples were 17 
analyzed by a restriction digest using the enzyme Bam HI.  The plasmid was digested at 
37°C for 1 hour and then run on a 1  % agarose gel at 80V for 1 hour.  If  the correct 
construct was obtained and in the correct orientation, the expected band size would be 
6000 b.p. Ifthe construct was in the incorrect orientation, the band sizes obtained would 
be 6000, 700 and 200 b.p. 
Large Scale Plasmid Prep of  RhoGAP/pcDNA3.1  nV5IDEST #14-J 
Bacteria from an overnight culture were used to start an 8-hour culture, which was then 
used to start an overnight culture.  DNA was extracted using an EndoFree Plasmid Maxi 
Kit according to manufacturer's instructions. The absorbance was read using a 
spectrophotometer, and the concentration was then calculated.  A restriction digest was 
performed on the sample using Bam HI at 37°C for 1 hour.  The digests were run on a 
1  % agarose gel at 80V for 1 hour.  Expected band size if  the correct construct is obtained 
would be 6000 b.p. If the correct construct is not obtained, the expected band sizes would 
be 200, 700, and 6000 b.p. 
Analysis of Mutant by DNA Sequencing 
One sample ofthe DNA was sent to a sequencing facility at the University of  California, 
Davis.  Sequences obtained from UC Davis were then analyzed using the program 
"Chromas."  The sequence will be sent in different lengths depending on the number of 
primers used.  A contig was then created from these sequences.  This contig was aligned 
with the DNA sequence originally designed for the mutant in order to determine ifthe 
correct clone was obtained. 18 
RhoGAPN5 Stable Line Transfection and Selection 
A stable line was attempted with our construct in order to decrease variability in future 
experiments in which this construct may be considered useful.  Another member ofthe 
lab transfected RhoGAPN5 plasmid DNA into HEK293 cells. HEK293 cells are known 
for their ability to readily transfect and are easy to work with.  FuGENE HD was used to 
transfect the cells. Once the cells were transfected, selection was done with geneticin. 
Selection works by means of killing off  cells that do not have the vector of interest, in 
this case our RhoGAPN5 construct.  Eventually, only the cells that contain our vector 
will remain on the plates. Selection is performed in order to ensure that each colony of 
cells is genetically identical. Once individual colonies have been isolated, they are 
allowed to grow and proliferate. After cells have been allowed to grow, they will be 
lysed, in order to analyze the protein being expressed in the cells. 
Analysis of RhoGAPV5 Stable Line 
Upon completion of  selection, cells were lysed/assessed for construct expression.  Cells 
were washed with a wash buffer composed of20mM Trizma (Sigma # TI378)/l37mM 
NaCI (Fischer # MSX04251)/lmM MgCL2-6H20 (VWR Scientific # EM-5980)/lmM 
CaCl2 dihydrate (VWR Scientific # EM-3000). The cells were then lysed open using a 
lysis buffer containing the same components as the wash buffer, with the addition of 10% 
glycerol (Invitrogen #15514-001)/1.0% NP40 (Sigma #74385).  On the day of  the 
experiment, 1 Mini-tab (Roche 1836153) was added to the lysis buffer to inhibit 
proteases.  This entire experiment was done on ice in order to further inhibit any protease 
activity.  Cells were scraped from the plate using a cold cell scraper and then transferred 19 
to a cold microcentrifuge tube. Cells were rocked at 4°C for 20 min. Cells are then 
centrifuged for 10 min at 1OOOOxg at 4°C. Supernatants transferred to pre-chilled tubes. 
Protein concentration was then determined.  The lysates were combined with blue 
dye. The dye should bind to the protein, which is expressed at different levels depending 
on the protein expression in the sample.  The samples were allowed to incubate for 5 min, 
in order to let the dye completely bind to the protein.  The absorbance will be read using 
a Microtiter plate reader and it will be read at 595 nm. 
A standard curve was established using samples of  known protein concentration. 
Serial dilutions were made of  the unknown samples.  The first sample was left undiluted, 
then diluted at 1:5 and 1: IO.  Samples were then placed in the plate reader, which not 
only reads the samples, but also thoroughly mixes the samples before the reading.  The 
plate reader creates a set of  data reporting the standard curve, the unknown sample 
concentrations, and absorbance values. 
Western Blot Analysis 
A PAGE gel was run with samples A-E.  There was also a V5 control used.  The gel was 
run at 200 V for 30 minutes.  The gel was then carefully placed into an XCell II Blot 
Apparatus.  This enables the protein from each ofthe samples on the PAGE gel to 
transfer onto a blot paper, in order to proceed with a Western Blot.  The first step was to 
block.  The PVDF membranes were re-wetted in 100% methanol. The membrane was 
then rinsed twice in distilled water and once in IX PBS.  The membrane is then placed 
directly into blocking buffer for 1 hour, shaking.  The next step is to probe.  The primary 
antibody must be diluted in a solution composed of  the following 40 mL LI-COR 
blocking buffer (927-400000)/40 J.!L Tween 20.  After mixed, 8 /-lL anti-V5 (Invitrogen 20 
R960-25) was added. The mixture is poured on the blot and rocked, covered at 4°C ON 
or for several days. Membranes were washed in IX PBS +0.1 % Tween-20 at RT; once 
briefly, twice for 5 minutes each. The membranes were  probed with IRDye secondary 
antibodies raised against species of  the primary antibodies.  In order to dilute the 
secondary antibody, a mixture of40 mL LJ-COR blocking buffer and 40 J-tL Tween 20 
was used. After mixed, 1 J-tL anti-mouse 800 (Rockland Immunochemicals) was added. 
The mixture was poured onto the blot and rocked at RT for no longer than I hour. 
Protection from light is important for the remainder of  the Western Blot. The blot was 
then washed in IX PBS +0.1 % Tween 20 at RT; once briefly, twice for 5 minutes each. 
The blot was then rinsed in PBS to remove residual Tween 20.  The membrane was then 
scanned using the LJ-COR odyssey imager. 
FAILED EXPERIMENTS 
Amplification of  RhoGAP Domain from WT p8S DNA 
Several times while attempting to amplify and isolate the RhoGAP domain of  p85, 
different sets of  PCR conditions had to be utilized in order to determine the optimal 
conditions necessary for PCR to work properly.  The annealing temperature was 
especially important in successfully amplifying the RhoGAP domain.  The optimal 
annealing temperature should be 5-1 O°C lower than the melting temperature of  the 
primers used.  The typical range is 55-65° C.  The annealing temperature was changed 
several times before the correct temperature was finally established. 
Infection to Assess Inhibition of Invasion 
The correct construct was not obtained before summer break commenced, therefore 
another member of  the lab picked up my work for the summer.  The correct construct was 21 
finally obtained as RhoGAP/pcDNA3.lnV5/DEST.  Cell culture work began with this 
construct.  The plasmid DNA was transfected into HEK 293 cells for infection studies. 
Once the construct was introduced into these cells, several attempts were made to obtain 
accurate and statistically significant data on the inhibition of  invasion ofS.  aureus 
following infection of  the cells.  Unfortunately, the results of  the experiments were 
inconsistent, therefore any further attempts to utilize RhoGAP/pcDNA3.1nV5/DEST to 
assess inhibition ofS.  aureus invasion was aborted. 
RESULTS 
Amplification of RhoGAP Domain 
The RhoGAP domain of WT p85 was amplified using a PCR reaction.  This allowed us 
to over express the Rho  GAP domain, which was useful in determining the effect of  over 
expression on S.  aureus invasion.  PCR was performed using WT p85 and a set of 
primers designed to specifically isolate our fragment of  interest.  After the PCR reaction, 
the reaction product was run on a 1  % agarose gel in order to determine if  the correct 
product was obtained. The gel was run at 80V for 1 hour and a band was expected at 
approximately 550 b.p.  After several unsuccessful trials of  our PCR reaction, the 
amplified RhoGAP domain was finally obtained (Figure 1) with the following PCR cycle 
conditions:  1 cycle:  95° C  2.5 min 
35 cycles:  95° C  15 sec 
60° C  1 min 
72° C  1 min 
4° C Eternity 22 
Cloning into pENTRID-TOPO Vector 
Once the amplified fragment, Rho GAP , was obtained, the process of  cloning our 
fragment into the pENTRlD-TOPO vector was started.  Once the reaction was complete, 
the reaction mixture was transformed into OneShot ToplO competent Cells.  A sample of 
pENTR control DNA was also transformed into competent cells. The cells were then 
allowed to shake at 37°C for 1 hour.  The samples were spread on kanamyacin plates and 
incubated ON.  Overnight cultures were started of  each sample.  DNA was extracted 
from the cells using a Qiaprep Spin Mini kit.  Cells were suspended in a combination of 
buffers in order to lyse open the cells, followed by a series of  washes in order to wash 
away any contamination.  The plasmid was then isolated and eluted with water.  A 
restriction digest was performed in order to verify that cloning into the vector was 
successful.  The samples were digested with Hind III  and the expected band sizes were 
2900 b.p. and 341  b.p. The expected bands were observed for samples #1,3,5,6 (Figure 
2). In order to further eliminate samples for the rest of  the project, another restriction 
digest was done with the enzyme Nhe I. The expected band sizes were 2900 b.p. and 341 
b.p. This digest was able to narrow it down to samples #3 and 5, in which the correct 
band sizes were observed (Figure 3). Once the correct construct was obtained, a large 
scale plasmid prep was performed in order to obtain more plasmid DNA of sample #'s 3 
and 5.  Each of  the samples were digested with Nhe I and Hind III separately and 
expected band sizes were 2900 b.p. and 341  b.p. if  the correct construct was obtained. 
Bands at 2900 b.p. and 341  b.p. were observed for both samples 3 and 5 (Figure 4). 
Therefore, these samples were used for the continuation ofthe project. 23 
Recombining  into pcDNA3.1nV5IDEST Vector 
Once the correct mutant, RhoGAP/pENTRJD-TOPO, was obtained, recombination into a 
new vector started.  LR recombination was used to recombine RhoGAP into the 
pcDNA3.lnV5/DEST vector.  The samples were then transformed into OneShot TopiO 
competent cells and overnight cultures were made.  The DNA was isolated using a 
QiaPrep Spin Mini Kit and was analyzed using restriction digest.  The samples were 
digested using Pst I and Bam HI separately. The digest was then run on an agarose gel. 
The expected band sizes if  the construct was in the correct orientation when digested with 
Pst I were ~4Il1 b.p. and -2000 b.p.  The expected band size ifthe construct was in the 
correct orientation when digested with Bam HI would be -6200 b.p. The expected band 
sizes were observed in samples 5D and 5F (Figure 5), however, sample #5D was used for 
the continuation ofthe experiment.  A large scale prep was done in order to obtain more 
plasmid DNA of  #5D.  A restriction digest was again performed on the sample to make 
sure that we still had the correct construct.  Two samples of#5D were digested, one with 
Pst I and one with Bam HI.  The expected band sizes were -4111 b.p. and -2000 b.p. 
for the digest with Pst I and -6200 b.p. for the digest with Bam HI.  The gel was initially 
run for 1 hour, however, further distinction between bands was necessary, so it run for 
another 45 minutes.  After 45 minutes, it was determined that the correct construct was 
again obtained with #5D. 
Analysis of  Mutant by DNA Sequencing 
The sample RhoGAP/pcDNA3.1nV5/DEST #5D was sent away for sequence 
confirmation at the University of  California-Davis Sequencing Facility.  Primers were 
used to span the length of  the RhoGAP fragment plus a small length ofvector on each 24 
side.  By sequencing, it can be detennined ifthe correct fragment was cloned into the 
vector, as well as ifthe fragment was in the correct orientation in the vector.  The 
sequences from the sequencing facility were analyzed using Chromas and Vector NTL  A 
contig was created from the separate fragment sequences.  This contig was then aligned 
with the DNA sequence originally designed for the mutant to determine ifthe correct 
sequence was obtained.  Unfortunately, the mutant construct was in the wrong orientation 
in our vector, therefore, it was necessary to start a new cloning reaction to detennine 
where the construct went into the vector backwards. 
Cloning into pENTRID-TOPO Vector Trial #2 
A new cloning reaction was perfonned in order to correctly insert the mutant construct 
into the RhoGAP/pENTRJD-TOPO vector.  The original Rho GAP PCRproduct was used 
for this cloning reaction. The new RhoGAP/pENTRJD-TOPO and original 
RhoGAP/pENTRJD-TOPO Mini Prep #6 bacterial cultures were used for transfonnation 
into cells.  The samples were transfonned into OneShot Top 10 competent cells and 
overnight cultures were obtained from each ofthe samples.  DNA was then extracted 
from each of  the samples using a QiaPrep Spin Mini Kit.  This plasmid DNA was then 
digested with both Hind III and EcoRV.  The expected band sizes were big, 374 b.p., and 
341  b.p. if  the construct is in the correct orientation.  Sample #14 has the expected bands 
at big, 374 b.p., and 341  b.p. which are the expected sizes for the mutant construct 
(Figure 6).  Ifthe construct was in the incorrect orientation in our vector, there would be 
a band present at 150 b.p. as well as the other bands, and that band is not observed in the 
image.  A large scale prep ofthe RhoGAP/pENTRJD-TOPO #14 sample was perfonned 
in order to obtain more plasmid DNA. A restriction digest was again performed to ensure 25 
that the construct was still in the correct orientation in the vector.  The sample was 
digested with Hind III and EcoRV and the expected band sizes were big, 374 b.p., and 
341  b.p.  The observed band sizes were consistent with the expected results (Figure 7), 
therefore RhoGAP/pENTRlD-TOPO #14 was used for the continuation of  the 
experiment. 
Analysis of Mutant by DNA Sequencing 
Once the correct construct was obtained, a sample ofthe DNA was sent away for 
sequence confirmation at DC Davis Sequencing Facility.  The sequences sent back from 
the facility were analyzed using Chromas and Vector NTL  A contig was created using 
the fragment sequences and the contig was aligned with the sequence originally designed 
for the mutant. The sequence of  RhoGAP/pENTRlD-TOPO #14 shares 100% identity 
with the originally designed RhoGAP/pENTRlD-TOPO.  Therefore, the Rho  GAP 
domain has been successfully cloned into pENTRlD-TOPO, the orientation is correct, 
and the domain can be cloned into destination vectors. 
Recombining into pcDNA3.1n  V5IDEST Vector 
Once the RhoGAP domain was successfully created and in the correct orientation in the 
pENTRlD-TOPO vector, recombination into a destination vector was started.  An LR 
recombination reaction was performed.  The samples were then transformed into 
OneShot TopiO competent cells.  DNA was extracted from the cells using a QiaPrep Spin 
Mini Kit and the plasmid samples were then digested using Hind III.  The expected band 
sizes if  the transformation was correct are 341  b.p., 166 b.p., and big.  Ifthe construct is 
in the incorrect orientation, the expected band sizes would be 341  b.p., 386 b.p., and big. 
The observed bands did not match the expected bands, therefore, the LR recombination 26 
and mini plasmid prep were repeated. The new samples were digested with a new 
enzyme as well.  Instead ofusing Hind III, the enzyme used was Bam HI.  Ifthe correct 
construct is obtained, the expected band size would be ~6000  b.p.  Ifthe construct was 
not correct, the expected band sizes would be 200 b.p., 700 b.p., and 6000 b.p. The 
expected band at ~6000 b.p. was observed in all six samples, therefore the experiment 
was continued with RhoGAP/pcDNA3.lnV5IDEST #14J.  A large scale plasmid prep of 
#14J was performed in order to obtain more plasmid DNA.  It was later determined that 
this construct was not correct via analysis by DNA sequencing (Data not shown). 
Western Blot Analysis of RhoGAPIVS Stable Line 
The RhoGAP/pcDNA3.lnV5/DEST samples were transfected into HEK293 cells to 
attempt to start a stable line expressing our mutant construct.  Once the cells had been 
transfected and selection had taken place, the cells were lysed open so that the protein 
being expressed could be analyzed.  The protein concentrations ofeach ofthe samples 
were determined using microtiter well plates and compared against a standard curve with 
proteins ofknown concentrations.  A PAGE gel was ran on the samples A-E and the V5 
controL  The membrane was then blocked and probed with primary antibody (anti-V 5) 
and secondary antibody (anti-mouse 800).  The membrane was imaged with the LI-COR 
Odyssey imager. A band is expected at about 30 kD ifthe clone is being stably expressed. 
The V5 positive control would produce a band at approximately 20 kD.  From the image, 
bands were observed at -30 kD in samples C and D.  Therefore, we believe that samples 
C and D were stably expressing our mutant (Data not shown). 27 
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Figure 1: peR product is generated. The sample was run on a 1  % 
agarose gel at 80V for 1 hour.  A low mass ladder was loaded into Lane 1, 
which represented band sizes between 2000 and 400 b.p. The sample was 
loaded into Lane 2.  The expected band size was 550 b.p. The peR 
product appeared to have the correct band size.  Therefore, this product 
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Figure 2: Samples #1,3, 5, 6 appear to be the correct construct.  The plasmid 
DNA was digested with Hind III for 1 hour at 37°C. The samples were then run 
on a 1  % agarose gel at 80V for 1 hour. A low mass ladder was loaded into Lane 
1, representing band sizes between 2000 and 100 b.p. An undigested sample was 
loaded into Lane 2 as a control. The expected band sizes ifthe correct construct 
was obtained were 2900 b.p. and 341  b.p. Samples #1,3,5,6 appear to be the 










Figure 3: Samples #3,5 appear to have the correct construct.  Samples were 
digested with Nhe I at 37°C for 1 hour.  The samples were then run on a 1  % 
agarose gel at 80V for 1 hour.  A low mass ladder was run in lane 1 representing 
band sizes from 2000 to 100 b.p. An undigested sample was run in lane 3 as a 
controL The expected band sizes if  the correct construct was obtained are 2900 
b.p. and 341  b.p. Samples #3 and 5 appeared to yield the correct clone. Therefore, 









Figure 4: Restriction digest of  RhoGAP/pENTRID-TOPO # 3, 5 large 
scale prep indicates that sample #5 appears to have the correct construct. 
Each sample was digested with Nhe I and Hind III separately at 37°C for 1 hour. 
The samples were then run on a 1  % agarose gel at 80V for 1 hour.  A low mass 
ladder was loaded into Lane 1 representing band sizes from 2000 to 100 b.p. An 
undigested sample was loaded into Lane 2 as a control.  The expected band sizes 
were 2900 and 341 b.p. if  the correct construct is obtained. Samples in Lanes 3 
and 5 appeared to be correct, therefore, we believe that Samples #3 and 5 are the 
















Figure 5: Sample #5 appears to be correctly cloned into 
RhoGAP/pcDNA3.1nV5fDEST. The samples were digested with both PstI (Top 
gel) and Bam HI (Bottom gel) separately at 37°C for 1 hour.  The samples were 
then run on 1% agarose gels at 80V for 1 hour.  A high mass ladder was loaded in 
lane 1 ofboth gels representing band sizes from 10000 to 1000 b.p. An undigested 
sample was run in the last lane ofeach gel.  The expected band sizes for digest 
with Pst! was 4111 and 2000 b.p. if  the recombination worked correctly. The 
expected band size for the digest with Bam HI was 6200 b.p. ifthe recombination 
worked correctly.  Samples #5D and 5F both appeared to be correct, however, 









Figure 6:  Sample #14 was successfully cloned into pENTRID-TOPO.  The 
samples were digested with Hind III and Eco RV simultaneously at 37°C for 1 
hour.  The samples were then run on a 1  % agarose gel at 80V for 1 hour.  A 
low mass ladder was loaded into lane 1 representing band sizes between 2000 
and 200 b.p. The expected band sizes if  the cloning reaction was successful and 
in the correct orientation were big, 374 b.p., and 341 b.p. Sample #14 in lane 5 
appears to have underwent cloning successfully. 33 
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Figure 7: Large scale prep of sample #14 indicated that it was 
successfully cloned. The sample was digested with Hind III and Eco RV 
at 37°C for 1 hour. The gel was then run on a 1  % agarose gel at 80V for 1 
hour. A low mass ladder was loaded into lane 1 representing band sizes 
from 2000 b.p. to 200 b.p. An undigested sample was loaded into lane 2. 
The expected band sizes ifthe cloning reaction was successful is big, 374 
b.p., and 341 b.p. Sample #14 appears to have been cloned correctly. 34 
DISCUSSION 
S.  aureus infection is becoming a serious problem in the health care industry 
today (Lowy, 1998). This type of  infection is becoming a cause for concern due to the 
antibiotic resistance that several strains ofthe bacteria have developed.  With this 
growing problem, several hospitals and healthcare communities have started to cycle 
antibiotics (Lipsitch, 2000).  Cycling occurs when one class of  antibiotics are used as 
primary treatment ofinfections for a period oftime, and then as resistance to this class 
climbs, they switch to emphasize use of  a second class of antibiotics to which resistance 
is rare or absent. Not only have several strains of  bacteria started to develop antibiotic 
resistance, the bacteria themselves are able to evade the host immune system in a 
different fashion. S.  aureus secretes proteins that lyse neutrophils, neutralize 
antimicrobial defensin peptides, and its overall cell surface is modified to reduce 
effectiveness of the host cell's defense mechanisms (Foster, 2005).  This resistance both 
by the bacteria, as well as to antibiotic treatment, increases the necessity for an alternate 
treatment for bacterial-induced sepsis. 
The purpose ofthe project was to over express the RhoGAP domain of  p85, the 
regulatory subunit ofPI3K, which is necessary for binding to small GTPases such as 
Cdc42.  By over expressing this domain, we hope to see an inhibition ofcellular invasion 
by S.  aureus. It has been previously shown that simvastatin is able to inhibit invasion 
dependent on a mechanism that operates through the cholesterol biosynthesis pathway 
(Horn, 2008).  If  cells are pre-treated with simvastatin, the production of  cholesterol, as 
well as several other important intermediaries, is blocked.  From these findings, it was 35 
determined that the depletion ofthe isoprenoid intermediates, Ggpp and Fpp, was a main 
reason for the decrease in S.  aureus invasion.  This can be concluded due to the fact that 
replenishment ofeach restored invasion and inhibition ofGgpp and Fpp decreased 
invasiveness (Horn, 2008).  These isoprenoid intermediates are important in localization 
ofproteins within the cell, notably those proteins that can become anchored at the cell 
membrane.  In the process ofpost-translational prenylation, Ggpp or Fpp are added at the 
cysteine residue ofthe carboxyl-terminal sequence, or Caax motif (Maltese, 1990).  This 
prenylation-interaction is important for Caax-containing proteins, such as Rac and Cdc42, 
due to the fact that this prenylation anchors the proteins to the cell membrane. 
As previously discussed, protein-protein interaction at the cell membrane is 
believed to playa large part in the endocytic pathway used by S.  aureus to invade the 
host cell.  Class IA PI3Ks are heterodimers ofp 110 catalytic and p85 regulatory subunits 
that mediate a variety of cellular responses to growth and differentiation factors 
(Brachmann, 2005).  The p85 regulatory subunit is of  particular interest in this project, 
due to the presence ofthe Rho GAP domain.  The Rho  GAP domain was first observed by 
Zheng et aI.  (1994) to be a 50 kDa protein segment found on the regulatory subunit, p85, 
which is known to interact with members ofthe Rho Family of  small GTPases, including 
Cdc42.  Upon interaction ofthe Rho  GAP domain ofp85 with a small GTPase, it is 
believed that PI3K will be able to translocate to the cell membrane and become activated. 
Activation ofPI3K catalyzes the production ofPIP3 at cell membranes, thus resulting in 
the recruitment and activation ofvarious signaling components to the cell membrane, 
some of  which have been implicated in the regulation of  the cytoskeleton (Chen, 2004). 36 
PI, PIP, and PIP2 are substrates known to be phosphorylated by its interaction with 
phosphoinositide 3-kinase.  Phosphoinositide (PI) is normally found at the cell 
membrane.  When PI3K is able to interact with small GTPases, PI3K may be brought to 
the cell membrane, where its catalytic subunit, p 110, is able to interact with PI.  When 
this occurs, PI, PIP, and PIP2 are phosphorylated.  PIP2 appears to be most readily used 
by Class IA PI3Ks, therefore, PIP3 is most often formed at the cell membrane. 
When PIP3 is produced, an important actin-bundling and adhesion protein, a­
actinin is recruited to the site ofPIP3 formation. It has been suggested that a-actinin 
interacts with phosphates ofPIP3 (Fraley, 2003).  As a-actinin interacts with PIP3, its 
actin binding domain becomes altered, which interferes with its actin bundling activity. 
When this bundling activity is impaired, actin stress fibers are able to disassemble from 
the cell membrane.  It is our hypothesis that when the actin stress fibers disassemble, the 
cell is not able to maintain its shape and rigidity, thereby allowing endocytosis to occur. 
Overall, it is believed that simvastatin blocks invasion ofS.  aureus by inhibiting the 
anchoring ofPI3K-bound small GTPases to the cell membrane, via prenylation of 
isoprenoid intermediates. Therefore, in my project we have attempted to recreate the 
same effect by altering the Rho  GAP domain ofp85.  By over expressing this domain, we 
hoped to compete with endogenous p85 for binding to small GTPases anchored at the cell 
membrane.  Ifendogenous p85 cannot reach the cell membrane to interact with small 
GTPases, then PI3K will be sequestered in the cytosol.  The interaction ofPI3K is 
necessary for the production ofPIP3; if  PIP3 is not produced, then a-actinin remains 
bound to actin stress fibers, and endocytosis cannot occur. 37 
Amplification of  the Rho  GAP domain from WT p85 was successful by means of 
a polymerase chain reaction.  Once the RhoGAP domain was isolated and amplified, it 
was cloned into the pENTRID-TOPO vector, which is an entry clone useful for 
recombination into destination vectors.  Upon completion of  several rounds ofcloning 
experiments, the RhoGAP/pENTRlD-TOPO plasmid underwent recombination into the 
destination vector, pcDNA3.lnV5/DEST.  Destination vectors are important for 
transfection into cell lines. As soon as the correct mutant was obtained, the sample was 
sent away for DNA sequencing. This step was important to ensure that the amplified 
RhoGAP domain was being expressed and in the correct orientation in the destination 
vector.  RhoGAP/pcDNA3.lnV5/DEST was transfected into HEK293 cells for further 
analysis of  the mutant construct.  Following transfection of  our mutant construct, 
infection studies commenced.  However, the infection studies were not able to produce 
consistent results regarding its effect on host cell invasion.  Although consistent results 
were not produced in response to infection of  cells with our mutant construct, a stable 
line was attempted with the construct for possible use in future experiments. 
RhoGAPIV5 stable lines were produced in HEK 293 cells.  These stable lines are 
composed ofcells that underwent selection from one individual colony, therefore, all 
cells within the line have identical DNA containing the mutant construct. 
Over expression ofthe Rho  GAP domain of p85 was one side of  an experiment 
involving the Rho  GAP domain.  The flip side of  my experiment was the deletion ofthe 
Rho  GAP domain, a project performed by another member ofthe lab.  i1RhoGAP was the 
mutant construct produced by deleting the RhoGAP domain ofWT p85.  This mutant 
construct essentially has the same effect as over expression ofthe RhoGAP domain. 38 
When the Rho  GAP domain ofp85 is deleted, PI3K cannot interact with the small 
GTPases anchored at the cell membrane. Because PI3K is not able to localize to the cell 
membrane, it is proposed that PIP3 is not produced. Because PIP3 is not produced, (X­
actinin could maintain its interaction with actin stress fibers, thus maintaining the shape 
and rigidity ofthe cell.  If  the actin stress fibers remain intact, the usual mechanism for S 
aureus invasion is not possible.  ARhoGAP was transfected into HEK 293 cells, through 
which infection studies could be done.  Once the mutant DNA was transfected into the 
cells, the cells underwent a series of  infections with S aureus. Upon analysis of  infection 
in the cells, it was determined that there was reduced bacterial invasion in the cells 
containing the mutant construct (Master's Thesis, Haaning 2008).  Following these 
studies, it was necessary to clone the ARhoGAP construct into an alternate vector for use 
in further experiments involving actin stress fibers.  For this part ofthe experiment, I 
became involved in order to initiate the cloning and recombination reactions for this 
construct. 
The bacteria S.  aureus is the most common cause of  infection (Lowy, 1998) 
leading to sepsis, and due to growing antibiotic resistance, an alternate solution to this 
problem is necessary.  By over expressing the Rho GAP domain of WT p85, we believed 
that bacterial infection by S  aureus would be inhibited or reduced.  However, infection 
studies yielded inconsistent data. Therefore, we were not able to conclude that over 
expression ofthe RhoGAP domain will inhibit S aureus invasion.  The deletion ofthe 
Rho  GAP domain however, has produced significant results with respect to bacterial 
invasion. 39 
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